SK bioscience Co.,Ltd. (KRX:302440)
South Korea
· Delayed Price · Currency is KRW 39,100
-50 (-0.13%)
Apr 18, 2025, 3:30 PM KST
SK bioscience Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Net Income | -53,881 | 22,318 | 122,452 | 355,139 |
| Depreciation & Amortization | 49,225 | 34,765 | 27,236 | 18,775 |
| Loss (Gain) From Sale of Assets | -14,259 | 68.06 | 434.6 | -23.62 |
| Asset Writedown & Restructuring Costs | 1.41 | 1,154 | - | - |
| Loss (Gain) From Sale of Investments | -24,162 | -13,777 | -36,875 | -892.14 |
| Provision & Write-off of Bad Debts | -81.7 | -29.33 | -21.08 | -9.4 |
| Other Operating Activities | -124,925 | 3,240 | -29,807 | 119,603 |
| Change in Accounts Receivable | -2,472 | 26,674 | -4,770 | -7,595 |
| Change in Inventory | 79,410 | 52,888 | -96,230 | -70,337 |
| Change in Accounts Payable | -1,243 | -7,683 | -52,759 | 46,536 |
| Change in Other Net Operating Assets | -35,632 | -90,271 | -54,620 | 75,397 |
| Operating Cash Flow | -128,020 | 29,346 | -124,958 | 536,594 |
| Capital Expenditures | -164,413 | -43,461 | -72,993 | -42,907 |
| Sale of Property, Plant & Equipment | 16,529 | 0.54 | 34.57 | 47.08 |
| Cash Acquisitions | -216,758 | - | - | - |
| Sale (Purchase) of Intangibles | -7,811 | -6,834 | -3,497 | -1,562 |
| Investment in Securities | 423,329 | 7,377 | 352,052 | -1,384,617 |
| Other Investing Activities | 2,688 | -2,361 | -2,951 | -235.56 |
| Investing Cash Flow | 53,564 | -45,279 | 272,647 | -1,421,940 |
| Short-Term Debt Issued | - | 1,000 | 48,742 | 11,324 |
| Long-Term Debt Issued | 192,057 | - | - | - |
| Total Debt Issued | 192,057 | 1,000 | 48,742 | 11,324 |
| Short-Term Debt Repaid | - | -45,425 | -16,196 | -50 |
| Long-Term Debt Repaid | -10,791 | -51,039 | -55,031 | -35,521 |
| Total Debt Repaid | -10,791 | -96,464 | -71,227 | -35,571 |
| Net Debt Issued (Repaid) | 181,266 | -95,464 | -22,485 | -24,247 |
| Issuance of Common Stock | 75,680 | 397.6 | 2,618 | 983,256 |
| Other Financing Activities | -4,467 | 5,484 | - | -628.09 |
| Financing Cash Flow | 252,479 | -89,583 | -19,867 | 958,380 |
| Foreign Exchange Rate Adjustments | 7,653 | 7,253 | -561.87 | 22.25 |
| Net Cash Flow | 185,676 | -98,262 | 127,259 | 73,056 |
| Free Cash Flow | -292,433 | -14,114 | -197,951 | 493,686 |
| Free Cash Flow Margin | -109.30% | -3.82% | -43.34% | 53.14% |
| Free Cash Flow Per Share | -3787.93 | -183.27 | -2570.08 | 6686.61 |
| Cash Interest Paid | 3,567 | 1,397 | 2,681 | 3,407 |
| Cash Income Tax Paid | 4,658 | 25,639 | 104,210 | 8,987 |
| Levered Free Cash Flow | -345,408 | 13,402 | -203,405 | - |
| Unlevered Free Cash Flow | -343,105 | 14,276 | -201,867 | - |
| Change in Net Working Capital | 133,586 | -37,298 | 224,497 | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.